236 related articles for article (PubMed ID: 33272565)
1. High-resolution X-ray structure of three microtubule-stabilizing agents in complex with tubulin provide a rationale for drug design.
Xiao Q; Xue T; Shuai W; Wu C; Zhang Z; Zhang T; Zeng S; Sun B; Wang Y
Biochem Biophys Res Commun; 2021 Jan; 534():330-336. PubMed ID: 33272565
[TBL] [Abstract][Full Text] [Related]
2. Molecular mechanism of action of microtubule-stabilizing anticancer agents.
Prota AE; Bargsten K; Zurwerra D; Field JJ; Díaz JF; Altmann KH; Steinmetz MO
Science; 2013 Feb; 339(6119):587-90. PubMed ID: 23287720
[TBL] [Abstract][Full Text] [Related]
3. Molecular modeling study on the tubulin-binding modes of epothilone derivatives: Insight into the structural basis for epothilones activity.
Jiménez VA; Alderete JB; Navarrete KR
Chem Biol Drug Des; 2017 Dec; 90(6):1247-1259. PubMed ID: 28632973
[TBL] [Abstract][Full Text] [Related]
4. Hallmarks of molecular action of microtubule stabilizing agents: effects of epothilone B, ixabepilone, peloruside A, and laulimalide on microtubule conformation.
Khrapunovich-Baine M; Menon V; Yang CP; Northcote PT; Miller JH; Angeletti RH; Fiser A; Horwitz SB; Xiao H
J Biol Chem; 2011 Apr; 286(13):11765-78. PubMed ID: 21245138
[TBL] [Abstract][Full Text] [Related]
5. Novel tubulin-targeting agents: anticancer activity and pharmacologic profile of epothilones and related analogues.
Fumoleau P; Coudert B; Isambert N; Ferrant E
Ann Oncol; 2007 Jul; 18 Suppl 5():v9-15. PubMed ID: 17656562
[TBL] [Abstract][Full Text] [Related]
6. Synthesis & antitumor activity of epothilones B and D and their analogs.
Cheng H; Huang G
Future Med Chem; 2018 Jun; 10(12):1483-1496. PubMed ID: 29788770
[TBL] [Abstract][Full Text] [Related]
7. The high-resolution X-ray structure of vinca-domain inhibitors of microtubules provides a rational approach for drug design.
Chengyong W; Jinghong X; Yanyan W; Qing-Jie X; Lingling M; Yuyan L; Hai C; Qian L; Quan Z; Bo S; Yuxi W
FEBS Lett; 2021 Jan; 595(2):195-205. PubMed ID: 33220079
[TBL] [Abstract][Full Text] [Related]
8. Characterizing the Epothilone Binding Site on β-Tubulin by Photoaffinity Labeling: Identification of β-Tubulin Peptides TARGSQQY and TSRGSQQY as Targets of an Epothilone Photoprobe for Polymerized Tubulin.
Ranade AR; Higgins L; Markowski TW; Glaser N; Kashin D; Bai R; Hong KH; Hamel E; Höfle G; Georg GI
J Med Chem; 2016 Apr; 59(7):3499-514. PubMed ID: 26986898
[TBL] [Abstract][Full Text] [Related]
9. The binding mode of side chain- and C3-modified epothilones to tubulin.
Erdélyi M; Navarro-Vázquez A; Pfeiffer B; Kuzniewski CN; Felser A; Widmer T; Gertsch J; Pera B; Díaz JF; Altmann KH; Carlomagno T
ChemMedChem; 2010 Jun; 5(6):911-20. PubMed ID: 20432490
[TBL] [Abstract][Full Text] [Related]
10. Development of other microtubule-stabilizer families: the epothilones and their derivatives.
Brogdon CF; Lee FY; Canetta RM
Anticancer Drugs; 2014 May; 25(5):599-609. PubMed ID: 24398663
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of isotopically labeled epothilones.
Ganesh T; Brodie PJ; Banerjee A; Bane S; Kingston DG
J Labelled Comp Radiopharm; 2014 Feb; 57(2):78-81. PubMed ID: 24307484
[TBL] [Abstract][Full Text] [Related]
12. Differentiating between models of epothilone binding to microtubules using tubulin mutagenesis, cytotoxicity, and molecular modeling.
Entwistle RA; Rizk RS; Cheng DM; Lushington GH; Himes RH; Gupta ML
ChemMedChem; 2012 Sep; 7(9):1580-6. PubMed ID: 22807375
[TBL] [Abstract][Full Text] [Related]
13. Epothilones as lead structures for new anticancer drugs--pharmacology, fermentation, and structure-activity-relationships.
Altmann KH; Memmert K
Prog Drug Res; 2008; 66():273, 275-334. PubMed ID: 18416309
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of ixabepilone, a novel epothilone analogue.
Pivot X; Dufresne A; Villanueva C
Clin Breast Cancer; 2007 Apr; 7(7):543-9. PubMed ID: 17509162
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis of Microtubule Stabilization by Discodermolide.
Prota AE; Bargsten K; Redondo-Horcajo M; Smith AB; Yang CH; McDaid HM; Paterson I; Horwitz SB; Fernando Díaz J; Steinmetz MO
Chembiochem; 2017 May; 18(10):905-909. PubMed ID: 28207984
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
17. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells.
Giannakakou P; Gussio R; Nogales E; Downing KH; Zaharevitz D; Bollbuck B; Poy G; Sackett D; Nicolaou KC; Fojo T
Proc Natl Acad Sci U S A; 2000 Mar; 97(6):2904-9. PubMed ID: 10688884
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents.
Fojo T; Menefee M
Ann Oncol; 2007 Jul; 18 Suppl 5():v3-8. PubMed ID: 17656560
[TBL] [Abstract][Full Text] [Related]
19. Epothilones: a novel class of microtubule-stabilizing drugs for the treatment of cancer.
Trivedi M; Budihardjo I; Loureiro K; Reid TR; Ma JD
Future Oncol; 2008 Aug; 4(4):483-500. PubMed ID: 18684060
[TBL] [Abstract][Full Text] [Related]
20. Structural insight into epothilones antitumor activity based on the conformational preferences and tubulin binding modes of epothilones A and B obtained from molecular dynamics simulations.
Jiménez VA; Alderete JB; Navarrete KR
J Biomol Struct Dyn; 2015; 33(4):789-803. PubMed ID: 24773261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
